Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma

Atsushi IsodaDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, JapanCorrespondence[email protected]

http://orcid.org/0000-0002-3080-2341

Tetsuya IshikawaDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan

Yuri MiyazawaDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan

Masahiro MiharaDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan

Morio MatsumotoDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan

Morio SawamuraDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan

References

Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441–3449.
PubMed Web of Science ®Google Scholar
San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–1206.
PubMed Web of Science ®Google Scholar
San-Miguel JF, Richardson PG, Günther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31:3696–3703.
PubMed Web of Science ®Google Scholar
Berdeja JG, Hart LL, Mace JR, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 2015;100:670–676.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date